ClinicalTrials.gg
RecruitingNCT07066098Updated Oct 5, 2026

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)

A Phase 3 interventional study of IBI343 and Placebo in Pancreatic Cancer, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Oct 5, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 630 studies in Pancreatic Neoplasms with a site in China — 334 open to participants now, 360 under way, 30 of them phase 3. Pancreatic Neoplasms · China.

Planned enrollment
96th of 508
201 · median 58
Started
2025
with 83 others
Phase 3
41 of 630
22 open now
Primary completion
2027-06
later than 240 of 359 live
Registered
525th of 630
by date

Among the 630 studies in Pancreatic Neoplasms with a site in China, this one is the 96th largest by planned enrollment of the 508 interventional ones that give a count, is one of 84 that started in 2025, is one of 41 in phase 3, reaches primary completion later than 240 of the 359 other live ones, and was the 525th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

334 of the 630 studies in Pancreatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

329 more — sign in →

All 334 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 630 studies in Pancreatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a study of a Multicenter, Randomized, Double-Blind, Phase III Study of IBI343 Monotherapy Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Participants with Claudin (CLDN) 18.2-Positive, Locally Advanced Unresectable or Metastatic Pancreatic Cancer Who Received at least 2 Prior Lines of Therapy. The primary objective of this study is to determine Overall Survival (OS) of IBI343 plus best supportive care (BSC) compared with placebo plus BSC.

Read the detailed description

This is a study of a Multicenter, Randomized, Double-Blind, Phase III Study of IBI343 Monotherapy Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Participants with Claudin (CLDN) 18.2-Positive, Locally Advanced Unresectable or Metastatic Pancreatic Cancer Who Received at least 2 Prior Lines of Therapy. It is planned to enroll 201 participants, and participants will be randomized to receive IBI343 plus BSC or placebo plus BSC in a 2:1 ratio.

03

Conditions studied

  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the written form (ICF) and be willing and able to comply with the visits and related procedures stipulated in the plan.
  2. confirmed unresectable locally advanced, or pancreatic cancer.
  3. Have received and progression after at least two systemic therapies(must including a fluorouracil-based and a gemcitabine-based therapy).
  4. PS score of 0 or 2.
  5. Adequate bone marrow and organ function
  6. Confirmed as CLDN18.2 positive.

Exclusion criteria

Exclusion Criteria:

  1. Participation in another interventional study, except observational or post-intervention follow-up.
  2. Prior treatment with topoisomerase inhibitor-based ADC.
  3. Has received the last dose of an anti-cancer therapy within 2 weeks or 5 half-lives (whichever is shorter) prior to the first dose of study treatment.
  4. Plans to receive other anti-tumor treatments during treatment with the study drug (palliative radiotherapy for symptomatic (e.g., pain) relief that does not affect response assessment is allowed) .
  5. Symptomatic ; asymptomatic brain metastases may be allowed with specific criteria.
  6. History of other primary , except cured or low-risk of recurrence.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
201 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    IBI343

    Drug: IBI343

  • Placebo comparator
    Control Arm

    Placebo

    Drug: Placebo

Interventions

  • DrugIBI343

    Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycle

  • DrugPlacebo

    Subjects in the control arm will receive placebo 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycle

06

What researchers measure

Primary outcomes

  1. overall survival(OS)

    Overall survival (OS) is defined as the time from randomization to death from any cause.

    Time frame: approximately 24 months

Secondary outcomes

  1. progression free survival(PFS)

    Progression-free survival (PFS) is defined as the time from random assignment in the trial to disease progression or death from any cause.

    Time frame: approximately 24 months

  2. Objective response rate (ORR)

    ORR is defined as the proportion of subjects in the analysis population who achieve confirmed objective response (CR or PR) per RECIST v1.1.

    Time frame: approximately 24 months

  3. disease control rate (DCR)

    DCR is defined as the proportion of subjects in the analysis population who achieve disease control (CR, PR, or SD) per RECIST v1.1 criteria.

    Time frame: approximately 24 months

  4. duration of response (DoR)

    DoR is defined as the time from the first CR or PR to disease progression or death from any cause, whichever occurs first for subjects with ORR per RECIST v1.1 criteria.

    Time frame: approximately 24 months

  5. time to response (TTR)

    TTR is defined as the time from randomization to the first CR or PR for subjects with ORR as assessed by IRRC per RECIST v1.1 criteria.

    Time frame: approximately 24 months

  6. Adverse Event

    Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0.

    Time frame: approximately 24 months

  7. Area under the plasma concentration versus time curve (AUC)

    area under the curve (AUC) of single and multiple doses of IBI343

    Time frame: approximately 24 months

  8. immunogenicity

    anti-drug antibody and/or neutralizing antibody

    Time frame: approximately 24 months

  9. maximum concentration (Cmax)

    maximum concentration (Cmax) of single and multiple doses of IBI343

    Time frame: approximately 24 months

  10. time to maximum concentration (Tmax)

    time to maximum concentration (Tmax) of single and multiple doses of IBI343

    Time frame: approximately 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

Of 84 phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 77. This study's planned 23 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2025 → Jul 2025, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 15, 2025
StartActual
Jul 17, 2025was Aug 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 4, 2025→Jul 17, 2025
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Start date Aug 4, 2025→Jul 17, 2025
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07066098
Responsible party
Sponsor
First posted
Jul 15, 2025
Start date
Jul 17, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Penglei Zheng
Contact
penglei.zheng@innoventbio.com
86-512-69566088

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arcotatug tavatecan

Start the discussion